"Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: Improvement in body surface area involvement in the phase 3 POETYK PSO-3 trial"
作者全名："Zhang, J.; Ding, Y.; Wang, P.; Li, L.; Pan, W.; Lu, Y.; Liu, L.; Kisa, R. M.; Hoyt, K.; Banerjee, S."
作者地址："[Zhang, J.] Peking Univ, Peoples Hosp, Beijing, Peoples R China; [Ding, Y.] Shanghai Skin Dis Hosp, Shanghai, Peoples R China; [Wang, P.] Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China; [Li, L.] Beijing Friendship Hosp, Beijing, Peoples R China; [Pan, W.] Peoples Hosp Zhejiang Prov, Hangzhou, Peoples R China; [Lu, Y.] Jiangsu Prov Hosp, Nanjing, Peoples R China; [Liu, L.; Kisa, R. M.; Hoyt, K.; Banerjee, S.] Bristol Myers Squibb, Princeton, NJ USA"
通信作者：
来源：JOURNAL OF INVESTIGATIVE DERMATOLOGY
ESI学科分类：CLINICAL MEDICINE
WOS号：WOS:001037960300631
JCR分区：Q1
影响因子：6.5
年份：2023
卷号：143
期号：5
开始页：S109
结束页：S109
文献类型：Meeting Abstract
关键词：
摘要：
基金机构：
基金资助正文：
